Goldman Sachs Group Inc Dbv Technologies S.A. Transaction History
Goldman Sachs Group Inc
- $555 Billion
- Q1 2024
A detailed history of Goldman Sachs Group Inc transactions in Dbv Technologies S.A. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 14,400 shares of DBVT stock, worth $12,096. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,400
Previous 46,805
69.23%
Holding current value
$12,096
Previous $44,000
77.27%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding DBVT
# of Institutions
35Shares Held
37.7MCall Options Held
0Put Options Held
0-
Baker Bros. Advisors LP New York, NY14.6MShares$12.3 Million0.14% of portfolio
-
Braidwell LP Stamford, CT7.84MShares$6.59 Million0.19% of portfolio
-
Yiheng Capital Management, L.P. San Francisco, CA5.57MShares$4.68 Million0.23% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.11MShares$2.61 Million0.01% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.71MShares$2.28 Million0.27% of portfolio
About DBV Technologies S.A.
- Ticker DBVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,776,992
- Market Cap $158M
- Description
- DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...